cCAM Biotherapeutics is a pre-clinical stage company that develops immunotherapies for cancer.
Acquired by Merck
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a
cancer specific immune response in patients.